drugset
Drugs / RT001
last change Aug 2022 re-read 3 minutes ago

RT001

also known as Botulinum toxin Type A · 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester

Protein / enzyme biologic

Developed for
eyelid disorder · Friedreich ataxia · amyotrophic lateral sclerosis · neuroaxonal dystrophy · progressive supranuclear palsy
Investigated by
Biojiva LLC · Revance Therapeutics, Inc.

Trials 8

today NCT04937530 · Ph 2 NCT04762589 · Ph 2 NCT04102501 · Ph 3 NCT03570931 · Ph 2/3 NCT02445794 · Ph 1/2 NCT01124565 · Ph 2 NCT01124552 · Ph 2 NCT00884234 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02445794 Aug 2015 → Jun 2016 Friedreich ataxia Biojiva LLC Completed No outcome recorded
Phase 25 trials
Phase 2 NCT04937530 Jun 2021 → Jul 2022 progressive supranuclear palsy Biojiva LLC Unknown No outcome recorded
Phase 2 NCT04762589 Mar 2021 → Jun 2022 amyotrophic lateral sclerosis Biojiva LLC Completed No outcome recorded
Phase 2 NCT01124565 May → Jul 2010 eyelid disorder Revance Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT01124552 Apr → Jul 2010 eyelid disorder Revance Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT00884234 Feb → Apr 2009 eyelid disorder Revance Therapeutics, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03570931 Nov 2018 → Aug 2020 overdue neuroaxonal dystrophy Biojiva LLC Active not recruiting No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT04102501 Oct 2019 → Aug 2021 Friedreich ataxia Biojiva LLC Completed Missed primary
Comparator or background therapy2 trials
Phase 2 NCT00907387 Comparator Apr → Oct 2009 eyelid disorder Revance Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT00888914 Comparator Nov 2008 → Jan 2009 eyelid disorder Revance Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as RT001 “RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester.” NCT02445794 ↗
9

NCT04102501 ↗

NCT04937530 ↗

NCT03570931 ↗

NCT01124552 ↗

NCT00907387 ↗

NCT04762589 ↗

NCT00884234 ↗

NCT00888914 ↗

NCT01124565 ↗
Known as 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester “RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester.” NCT04102501 ↗
Known as Botulinum toxin Type A “RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas” NCT01124565 ↗
1

“RT001 (Botulinum toxin Type A)” NCT01124552 ↗
Modality Protein / enzyme biologic “RT001 (Botulinum Toxin Type A Topical Gel)” NCT00884234 ↗
Route Topical “Botulinum Toxin Type A Topical Gel” NCT00884234 ↗